{"id":3430,"date":"2022-06-08T17:36:25","date_gmt":"2022-06-08T21:36:25","guid":{"rendered":"https:\/\/albanyentandallergy.fm1.dev\/?page_id=3430"},"modified":"2023-07-03T18:30:19","modified_gmt":"2023-07-03T22:30:19","slug":"clinical-research","status":"publish","type":"page","link":"https:\/\/albanyentandallergy.com\/clinical-research\/","title":{"rendered":"Hearing Study | FX-322"},"content":{"rendered":"\n
\n

Can a single dose medication potentially restore lost hearing? We\u2019re working to find out.<\/strong><\/p>\n\n\n\n

The physicians of Albany ENT and Allergy Services are helping to lead the charge and conducting clinical studies regarding FX-322, a new investigational drug that aims to activate and restore cells in the inner ear needed for healthy hearing.<\/p>\n\n\n\n

There are no costs for you to participate. If it is determined that you qualify for the study, you will receive all study related care, including medical tests, clinical care, investigational study drug, and study-related travel all at no cost to you.<\/p>\n\n\n\n

Your participation in this study will last for up to 10 months, during which you may have up to 8 in person study visits. Participation is completely voluntary and you may discontinue at any time.<\/p>\n<\/div>

\"\"<\/figure><\/div>\n\n\n\n

<\/p>\n\n\n\n

\n
\n
\"\"<\/span><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n

Inclusion Criteria<\/h2>\n\n\n\n